Tenax Therapeutics Inc. (TENX) posted a Q4 2025 net loss of $0.38 per share. The clinical-stage pharmaceutical company develops novel cardiopulmonary therapies in the United States.
Tenax’s pipeline includes TNX-101, TNX-102, and TNX-103 (levosimendan), which have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension. The company also develops TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
The company operates in the specialty pharmaceutical sector, focused on cardiovascular and pulmonary conditions.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.